Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 75
Inquire Before Buying

Global Markets Direct's, ‘Actinic (Solar) Keratosis - Pipeline Review, H2 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis

  • The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects

  • The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Actinic (Solar) Keratosis Overview 9
Therapeutics Development 10
Pipeline Products for Actinic (Solar) Keratosis - Overview 10
Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11
Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12
Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 13
Actinic (Solar) Keratosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Actinic (Solar) Keratosis - Products under Development by Companies 18
Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 19
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 20
3M Drug Delivery Systems 20
Athenex, Inc. 21
Digna Biotech, S.L. 22
Foamix Pharmaceuticals Ltd. 23
G&E Herbal Biotechnology Co., Ltd. 24
Galderma S.A. 25
Laboratories Ojer Pharma S.L. 26
LEO Pharma A/S 27
Novartis AG 28
Oncology Research International Limited 29
Promius Pharma, LLC 30
Spherium Biomed S.L. 31
Valeant Pharmaceuticals International, Inc. 32
Vectura Group Plc 33
Actinic (Solar) Keratosis - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
854-A - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ACT-01 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
AD-17137 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
celecoxib - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
DFD-08 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
disitertide - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
hydrogen peroxide + sulindac - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
IDP-125 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IDP-128 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
imiquimod - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
imiquimod SR - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
KX-01 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
LEO-43204 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
LFX-453 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ORIL-007 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
resiquimod - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
SKP-024 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SP-12054 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SRT-100 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
VDA-1102 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
VPE-001 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Actinic (Solar) Keratosis - Dormant Projects 70
Actinic (Solar) Keratosis - Discontinued Products 72
Actinic (Solar) Keratosis - Product Development Milestones 73
Featured News & Press Releases 73
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H2 2016 10
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Comparative Analysis by Unknown Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2016 20
Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H2 2016 21
Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2016 22
Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 23
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 24
Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2016 25
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 26
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2016 27
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H2 2016 28
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H2 2016 29
Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2016 30
Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H2 2016 31
Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 32
Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H2 2016 33
Assessment by Monotherapy Products, H2 2016 34
Assessment by Combination Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 39
Number of Products by Stage and Route of Administration, H2 2016 41
Number of Products by Stage and Molecule Type, H2 2016 43
Actinic (Solar) Keratosis - Dormant Projects, H2 2016 70
Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H2 2016 71
Actinic (Solar) Keratosis - Discontinued Products, H2 2016 72

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H2 2016 10
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 34
Number of Products by Top 10 Targets, H2 2016 36
Number of Products by Stage and Top 10 Targets, H2 2016 36
Number of Products by Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38
Number of Products by Routes of Administration, H2 2016 40
Number of Products by Stage and Routes of Administration, H2 2016 40
Number of Products by Molecule Types, H2 2016 42
Number of Products by Stage and Molecule Types, H2 2016 42
  • Global Cancer Gene Therapy Market Research Report 2017
    Published: 04-Dec-2017        Price: US 2900 Onwards        Pages: 120
    In this report, the global Cancer Gene Therapy market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cancer Gene Therapy in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 524
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades......
  • Ewing Sarcoma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 326
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape. Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The ......
  • Meningioma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 229
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2017, provides an overview of the Meningioma (Oncology) pipeline landscape. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, wi......
  • Gallbladder Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 179
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape. Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history......
  • Hepatocellular Carcinoma - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2500 Onwards        Pages: 1120
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape. Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in......
  • Cervical Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 674
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape. Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical......
  • Vaginal Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 92
    Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape. Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal in......
  • Vulvar Cancer - Pipeline Review, H2 2017
    Published: 30-Nov-2017        Price: US 2000 Onwards        Pages: 92
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape. Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases tu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs